New England Deaconess Hospital Corporation

Other

Sandoz Gmbh

Baxter Travenol Laboratories, Inc.

Kabivitrum Ab

George L Blackburn

Bruce R Bistrian

Vigen K Babayan

Edward Anthony Mascioli

Lyle L Moldawer

John T Daly

Richard Cotter

Jerome J Licari

J Wesley Alexander

John E Kinsella

Charles T Van Buren

Vigen R Babayan

Frank B Cerra

Frederick Rudolph

Mitchell T Gersovitz

The invention provides immunostimulatory compositions comprising an aggregate immunostimulatory amount of

Compositions and methods for the enhancement of host defense mechanisms

The present invention features a transesterification product of a mixture of fatty acids and triglycerides which include dairy fat as a primary component. This composition shows unexpected benefits in nutritional applications either as a food or as an enteral or parenteral supplement. The method of nutritional support using this composition is also disclosed.

Structured lipid containing dairy fat

A method of treating cancer cachexia syndrome has been discovered. Total parenteral nutrition using structured lipids in place of long chain fatty acids as the primary lipid source provides improvements in nitrogens balance, plasma serum albumin levels, and glucose clearance rate.

Nutritional supplement for treatment of cancer cachexia

A new dietary supplement has been developed which yields the benefits of both .omega.3 oils and medium chain triglycerides for lipid nutrition. A structured lipid containing .omega.3 fatty acids and medium chain fatty acids is also disclosed.

Dietary supplement utilizing .omega.-3/medium chain trigylceride mixtures

Chemically synthesized structured triglycerides (lipids) for enteral administration as the lipid calorie source, is subjects undergoing severe metabolic stress.

Triglyceride preparations for the prevention of catabolism

Disclosed is a method of minimizing infection and minimizing the risks of infection in at risk animals and patients. A dietary supplement to accomplish this objective is also disclosed. The method includes the step of administering a diet rich in .omega.3 fatty acids, for example by adding a substantial proportion of fish oils to the diet. The dietary supplement is particularly well suited to patients receiving total parenteral nutrition. A parenteral diet or diet supplement containing a mixture of oils, one rich in .omega.3 fatty acids and the other rich in .omega.6 fatty acids is disclosed.

Parenteral dietary supplement and method of minimizing effects of

A method of treating, and a diet composition for treating patients needing a controlled diet, wherein C.sub.12 fatty acids are the primary fatty acid source. Preferably lauric fats constitute 33-80% of the diet, while LCT's constitute no more than 20%. The lauric fats may be derived from a natural or fractionated kernel oil, selected from a group consisting of babassu oil, coconut oil, cohune oil, palm kernel oil, and tucum oil. A lipid emulsion with diverse additives is described.

Kernel oils and disease treatment

Disclosed is a method of minimizing infection and minimizing the risks of infection in at risk animals and patients. A dietary supplement to accomplish this objective is also disclosed. The method includes the step of administering a diet rich in .omega.3 fatty acids, for example by adding a substantial proportion of fish oils to the diet. The dietary supplement is particularly well suited to patients receiving total parenteral nutrition.

Method of minimizing efects of infection through diet

Medium chain triglyceride containing lipid emulsions for the nutrition of liver diseased or septicemic patients are improved by the inclusion in the emulsions of long chain triglycerides. The emulsions may also contain amino acids in proportions desirable for the nutrition of liver diseased patients, as well as carbohydrates, drugs, vitamins and electrolytes.

Parenteral nutrition with medium and long chain triglycerides

Exogenous LEM (Leukocyte Endogenous Mediator, also referred to as endogenous pyrogen) is parenterally administered to humans who are protein malnourished and are infected with bacteria, in order to preinitiate and then maintain the normal metabolic responses to the tissue damage occurring during infection, and thereby promote the normal metabolic response by the human.

Treatment of protein malnourished bacterially infected humans with LEM

Method and composition for enhancing protein anabolism in an hypercatabolic mammal. The method comprises parenterally administering to the mammal nutritionally sufficient sources for amino acids, carbohydrates and lipids, the lipids comprising a controlled triglyceride source which, on hydrolysis, yields both long chain fatty acids and medium chain fatty acids, preferably about 20 to 80% long chain fatty acids and about 80 to 20% medium chain fatty acids. In one embodiment, the composition has the additional benefit of being capable of providing more than 60% of the total caloric requirements of the mammal via the lipid source without immunological impairment of the reticuloendothelial system of the mammal.

Controlled triglyceride nutrition for hypercatabolic mammals

Exogenous LEM (Leukocyte Endogenous Mediator, also referred to as endogenous pyrogen) is parenterally administered to humans who are protein malnourished and are to undergo surgery, in order to preinitiate and then maintain the normal metabolic responses to the tissue damage occurring during surgery, and thereby promote the normal metabolic response by the human (patient).

Treatment of protein malnourished surgical patients

Disclosed is a novel nutritional branched chain amino acid composition and its use for treatment of a patients suffering stress or injury, especially useful for parenteral or enteral alimentation of a patient suffering total or partial dysfunction or disuse of the gastrointestinal tract. The novel composition promotes and even optimizes patient wound healing, immune competence, host defense, and/or survival. The amino acids comprise from about 70 to 100% valine, isoleucine, and leucine, collectively, in a ratio of A:B:C, respectively, where A, B and C each independently has value from about 1 to 2. The novel composition is preferably used in the form of a parenteral infusion solution of from about 2 to 6%, most preferably 4% concentration.

Growing community of inventors

Jamaica Plain, MA, United States of America

George L Blackburn